GSK's Trelegy and Breo Offer Incremental Improvement Over Generics

Trelegy Ellipta and Breo Ellipta, two drugs selected to be part of the next set of drugs to be assessed under Medicare’s drug price negotiation program, offer the advantage of requiring only one puff once a day compared with other therapies to treat chronic obstructive pulmonary disease (COPD) treatments, according to a special report issued by the Institute for Clinical and Economic Review (ICER). Both inhaler therapies were developed by GSK.